Amneal Pharmaceuticals is a holding company. Through its subsidiaries, Co. is a pharmaceutical company that develops, manufactures, markets, and distributes a portfolio of medicines, including generics, injectables, biosimilars and specialty branded pharmaceuticals. Co. has three reportable segments: Generics, which includes various product families covering a range of dosage forms and delivery systems; Specialty, which is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system disorders; and AvKARE, which provides pharmaceuticals, medical and surgical products, and services. The AMRX average annual return since 2018 is shown above.
The Average Annual Return on the AMRX average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether AMRX average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AMRX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free AMRX Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
